Provided by Integrity Continuing Education.
Supported by an educational grant from Sunovion Pharmaceuticals, Inc.
Bipolar disorder is a complex illness, and its diagnosis and management remain among the most challenging facets of clinical psychiatry. Patients with bipolar disorder are most likely to present with depression and are often misdiagnosed with unipolar depression. Many patients wait years for a correct diagnosis. Distinguishing between unipolar and bipolar depression is often difficult, and the frequent occurrence of mixed features can make the differential diagnosis challenging. Medical and psychiatric comorbidities are also common in patients with bipolar depression and complicate the diagnosis and treatment. Persons with bipolar disorder have a high incidence of metabolic syndrome and other cardiovascular risk factors, while obesity and inactivity are associated with more severe illness and poorer treatment outcomes. Anxiety disorders and substance use disorder are among the most common psychiatric comorbidities in patients with bipolar disorder.
Accurate diagnosis and consideration of comorbidities can prevent inappropriate or ineffective pharmacotherapy. This activity will provide insights to enhance healthcare providers’ knowledge of the accurate diagnosis and pharmacotherapeutic treatment of bipolar disorder. An expert faculty will discuss practical patient-centered strategies for diagnosis and management of bipolar depression, considerations for medical and psychiatric comorbidities, and evidence-based treatment strategies for bipolar depression. This is a Twitter-based tutorial designed to provide key information in an accessible format and location.
Leslie Citrome, MD, MPH
Psychiatry & Behavioral Sciences
New York Medical College
Valhalla, New York
This educational activity has been designed to meet the needs of psychiatrists and psychiatric nurse practitioners and physicians assistants involved in the management of patients with bipolar disorder.
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME credit for this activity. During the period of November 19, 2021 through November 19, 2022 participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.
Physician Continuing Education
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Integrity Continuing Education designates this other activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or firstname.lastname@example.org.
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Leslie Citrome, MD, MPH
Royalty: Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics), International Journal of Clinical Practice, through end 2019), Springer Healthcare (book), UpToDate (reviewer), Wiley (Editor-in-Chief)
Consulting Fees (eg, advisory boards): AbbVie, Acadia, Alkermes, Allergan, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Noven, Osmotica, Otsuka, Relmada, Sage, Shire, Sunovion, Takeda, Teva, University of Arizona
Speakers’ Bureaus: AbbVie, Acadia, Alkermes, Allergan, Angelini, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sage, Shire, Sunovion Pharmaceuticals, Inc., Takeda, Teva
Ownership Interest: Stocks (small number of shares of common stock): Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer purchased > 10 years ago
The Integrity Continuing Education planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.